Tamtam Try Tamtam free
Azelis logo

Azelis account plan

Specialty chemicals, food ingredients

At a glance

Azelis is an Antwerp-based distributor of speciality chemicals and food ingredients with 65,000+ customers: EUR 4,111m FY2025 revenue.

Azelis Group NV, headquartered in Antwerp and listed on Euronext Brussels (AZE, BEL20), distributes speciality chemicals and food ingredients and acts as an outsourced sales, marketing and technical arm for producers (its principals). It serves 65,000+ customers through 2,800+ principal relationships and 70+ application and formulating labs, and is present in 64 countries. FY2025 revenue was EUR 4,111m (-2.4%, +1.3% in constant currency), adjusted EBITA EUR 411m (10.0% margin) and net profit EUR 113m, with 4,189 FTEs. Life Sciences generated EUR 2,609m of revenue and Industrial Chemicals EUR 1,502m.

Business units

Strategic priorities

Market segment leadership
Azelis wants to be the reference partner in defined segments of Life Sciences and Industrial Chemicals, using cross-selling, smart pricing and a curated portfolio; a Group Commercial Excellence Director was appointed in 2025.
Active consolidator
Since 2017 Azelis has made over 60 acquisitions; the four 2025 bolt-ons (Solchem, S. Amit, ACEF, Distona) add over EUR 110.0m of annual revenue. The CEO says Azelis does not want to overpay while sellers keep high expectations.
One agile Azelis and AI-enabled back offices
Local organisations run on one ERP, one CRM and a central data lake; shared service centres are rolled out in each region, notably for finance, and over 200 customer portals are live.
2026-2031 medium-term targets
Announced on 29 September 2026: mid to high single-digit annual gross profit growth, high single-digit annual adjusted EBITA growth, a doubling of EPS by 2031 and ROCE > 11.5% by 2031.
Deleveraging and cash discipline
Leverage of 3.3x at end-2025 is "on the high side"; management aims not to be too far from 3.0 and to keep the BB+ rating, after delivering EUR 20 million of cost savings.

Latest results

Q3 2026 revenue was EUR 1,122m, +8.5% in constant currency with organic growth of 8.2%, and nine-month revenue EUR 3,288m (+4.9%). Industrial Chemicals drove the quarter with revenue of EUR 451m (+21.0%), while Life Sciences grew 1.5% to EUR 671m; all regions grew. Adjusted EBITA rose 14.6% to EUR 114m (10.2% margin). Inventories rose to support demand (DIO 59 days), cutting free cash flow to EUR 67m, and leverage stood at 3.46x after a EUR 350m non-cash goodwill impairment in the Americas. Azelis remains confident of positive organic adjusted EBITA growth for full-year 2026.

Investments and deals

2025 bolt-on acquisitions
Solchem Nature (Spain, nutraceuticals), S. Amit Group (India, performance chemicals), ACEF (Italy, Personal Care) and Distona (Switzerland, industrial chemicals) added EUR 61.1 million of revenue in 2025; 2025 M&A cash-out was about EUR 230 million including deferred payments.
Bond refinancing
In March 2026 a EUR 400 million 4.125% bond due 2031 replaced the 5.75% bond due 2028, saving about EUR 6.5 million of coupon a year.
Vogler Ingredients buy-out
In April 2026 Azelis bought out the non-controlling interests in Vogler Ingredients in Brazil.
Digital and lab network
Azelis runs 70+ application and formulating labs, is rolling out version 3.0 of its principal portal and is embedding AI in most processes; holding company costs rose on higher IT investments.

Challenges and risks

Volatile end-market demand
Tariff uncertainty, customers unwilling to build stock and the Middle East conflict keep volatility high; EMEA Life Sciences and Flavours & Fragrances stayed soft in 2026.
Chinese competition on semi-commodities
Increased supply from China pressures the 15%-20% semi-commodity part of the portfolio, especially in Southeast Asia, Africa, Brazil and Mexico.
Leverage and working capital
Net debt was EUR 1,640m and leverage 3.46x in Q3 2026; working capital rose to 17.2% of revenue and nine-month free cash flow fell 35.2%.
Dependence on principals
The top ten principals supplied 33.3% of 2025 revenue, and some principals take customers back in-house or rationalise distributor networks.
Cybersecurity
Cybersecurity is the first of the six top business risks named in the 2025 Integrated Report.

What leadership says

“Many of the green shoots we saw earlier this year have taken root, despite continued market volatility.”

Anna Bertona, Group CEO · Q3 2026 results release, 2026-10-22

“This is the time to make bold actions that will pay off when the cycle turns, and the cycle will turn.”

Anna Bertona, Group CEO · Full-year 2025 results call, 2026-02-19

“We are operating in an environment where volatility has become the norm rather than the exception.”

Anna Bertona, Group CEO · H1 2026 results call, 2026-07-30

“In any given year, our net wins are always more than our losses. Also this year that's the case.”

Anna Bertona, Group CEO · H1 2026 results call, 2026-07-30, on principal relationships

Where a supplier can help

Shared services and finance automation
Building AI-enabled back offices and regional shared service centres (one agile Azelis priority) creates demand for finance automation, process mining and AI tooling.
Inventory and working capital tools
With DIO back up to 59 days and working capital at 17.2% of revenue (leverage challenge), demand planning, inventory optimisation and receivables tools support the deleveraging goal.
Acquisition integration
As an active consolidator integrating each acquisition onto one ERP and CRM, Azelis needs data migration, integration and change management partners.
Cybersecurity
Cybersecurity is the top named risk for a group running customer and principal portals on a single platform, opening the door to security and resilience providers.
Lab and formulation capabilities
The 70+ labs and the push to increase specialties in APAC (segment leadership priority) point to lab equipment, formulation software and regulatory data services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Azelis?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Azelis

What does Azelis do?

Azelis distributes speciality chemicals and food ingredients, co-develops formulations with customers in its labs and acts as an outsourced sales and marketing arm for producers across Life Sciences and Industrial Chemicals.

What is Azelis's revenue?

FY2025 revenue was EUR 4,111m with adjusted EBITA of EUR 411m. Nine-month 2026 revenue was EUR 3,288m, up 4.9% in constant currency.

How many employees does Azelis have?

Azelis had 4,189 FTEs at the end of 2025 and describes itself as having over 4,100 employees in 64 countries.

What is Azelis's strategy?

The strategy rests on market segment leadership, an active role in consolidation and one agile Azelis platform, supported by innovation, sustainability and digitalisation. Its 2026-2031 targets include doubling EPS by 2031.

Who leads Azelis?

Anna Bertona has been CEO since 1 January 2024, Kare Schultz chairs the board, and Boris Cambon-Lalanne became Group CFO in January 2026.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)